Previous close | 45.93 |
Open | 46.33 |
Bid | 45.40 x 200 |
Ask | 45.46 x 200 |
Day's range | 45.25 - 46.81 |
52-week range | 42.08 - 77.32 |
Volume | |
Avg. volume | 1,000,611 |
Market cap | 8.261B |
Beta (5Y monthly) | 0.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Optimism started to prevail, during the last months of the year, and investors reacted positively to news of a potential change in direction by the US Federal Reserve, as well as […]